1. Home
  2. ATRA vs COEP Comparison

ATRA vs COEP Comparison

Compare ATRA & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATRA
  • COEP
  • Stock Information
  • Founded
  • ATRA 2012
  • COEP 2017
  • Country
  • ATRA United States
  • COEP United States
  • Employees
  • ATRA N/A
  • COEP N/A
  • Industry
  • ATRA Biotechnology: Biological Products (No Diagnostic Substances)
  • COEP Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ATRA Health Care
  • COEP Health Care
  • Exchange
  • ATRA Nasdaq
  • COEP Nasdaq
  • Market Cap
  • ATRA 39.7M
  • COEP 32.4M
  • IPO Year
  • ATRA 2014
  • COEP N/A
  • Fundamental
  • Price
  • ATRA $6.86
  • COEP $10.45
  • Analyst Decision
  • ATRA Buy
  • COEP
  • Analyst Count
  • ATRA 6
  • COEP 0
  • Target Price
  • ATRA $25.70
  • COEP N/A
  • AVG Volume (30 Days)
  • ATRA 71.1K
  • COEP 60.3K
  • Earning Date
  • ATRA 03-07-2025
  • COEP 05-09-2025
  • Dividend Yield
  • ATRA N/A
  • COEP N/A
  • EPS Growth
  • ATRA N/A
  • COEP N/A
  • EPS
  • ATRA N/A
  • COEP N/A
  • Revenue
  • ATRA $128,940,000.00
  • COEP N/A
  • Revenue This Year
  • ATRA N/A
  • COEP N/A
  • Revenue Next Year
  • ATRA N/A
  • COEP N/A
  • P/E Ratio
  • ATRA N/A
  • COEP N/A
  • Revenue Growth
  • ATRA 1404.02
  • COEP N/A
  • 52 Week Low
  • ATRA $5.40
  • COEP $2.31
  • 52 Week High
  • ATRA $20.83
  • COEP $13.70
  • Technical
  • Relative Strength Index (RSI)
  • ATRA 41.62
  • COEP 48.25
  • Support Level
  • ATRA $5.94
  • COEP $10.00
  • Resistance Level
  • ATRA $7.02
  • COEP $11.75
  • Average True Range (ATR)
  • ATRA 0.58
  • COEP 1.07
  • MACD
  • ATRA 0.07
  • COEP -0.12
  • Stochastic Oscillator
  • ATRA 52.36
  • COEP 48.22

About ATRA Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

About COEP Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

Share on Social Networks: